RCT1100

DB18830InvestigationalNucleic Acid Based Therapies

RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.

Mechanism: Pharmacologically active on Dynein axonemal intermediate chain 1
Curator reviewed
Code names: RCT1100

Resolves to

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with RCT1100, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.